Behind the Success of Singapore’s Healthcare and Biomedical Startups
Singapore has always been regarded as a hotspot for startup growth and innovation.
Singapore has always been regarded as a hotspot for startup growth and innovation.
HistoIndex announces the expansion of its AI-based digital pathology platform towards large-scale NASH preclinical programs for pharmaceutical and biotech companies to achieve quantifiable and reproducible data on therapeutic responses in NASH animal models, and to aid CROs as well as research agencies in validating new models mimicking the NASH disease.
HistoIndex Pte Ltd (Singapore) has joined the LITMUS partnership, all working towards the common goals of developing, validating and qualifying better biomarkers for testing NAFLD.
In a cross border collaboration, HistoIndex and the Institute of Liver & Biliary Sciences (ILBS) in New Delhi, India has jointly launched a Centre of Excellence (CoE) to aid diagnostics and clinical trials focusing on NASH.
A Singapore General Hospital (SGH) team, in collaboration with HistoIndex, has developed an automated test for quantifying fatty liver disease.
“The success of a medtech start-up is defined by the global impact of its products. For us, our solutions are being used by pharmaceuticals [in US clinical trials],” says Gideon Ho, CEO of HistoIndex.
HistoIndex is partnering with the University of Malaya and Pathomics Health to roll out an integrative diagnostics platform for the holistic analysis of patient tumor biopsies.
Laennec® has achieved its first regulated in vitro diagnostics (IVD) product status with the issuance of a Health Sciences Authority (HSA) Class A licence.